A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
Supplementary Data
Supplementary Data
Files in this Data Supplement:
Supplementary Figure 1
- doc file
Supplementary Figure 2
- doc file
Supplementary Figure 3
- doc file
Supplementary Table 1
- doc file
Supplementary Table 2
- doc file
Supplementary Table 3
- doc file